Every second, someone in the world is newly infected with tuberculosis (TB), a highly contagious air-borne disease.
The global burden of TB remains significant.
Success in stabilising the global tuberculosis (TB) epidemic is threatened by the emergence and spread of drug-resistant (DR) strains.
Over sixty per cent of the global burden of tuberculosis occurs in Australia’s neighbouring countries, particularly in Papua New Guinea.
TB is a leading cause of infectious disease morbidity and mortality. In 2012, there were an estimated 8.7 million new cases of TB (13 per cent of whom were co-infected with HIV) and 1.3 million people died from the disease. An additional 640,000 people had multidrug-resistant TB in 2012.
An infectious disease caused by the bacteria, Mycobacterium tuberculosis, it commonly affects the respiratory system. This can result in a range of symptoms such as coughing, chest pain, weight loss and weakness, fever and night sweats. The bacteria is transmitted from person to person via droplets from the throat and lungs of people with the active respiratory disease.
Burnet’s TB research
Burnet is actively involved in TB research with our unique ability to address health system management and support community interventions, through to leading molecular epidemiology studies and innovation in diagnostics for tuberculosis.
Burnet’s TB Working Group include:
Associate Professor David Anderson (Head of Burnet Institute’s TB program), Dr Emma McBryde, Dr Jack Richards, Dr Suman Majumdar, Professor Suzanne Crowe AM, Professor Margaret Hellard, Dr James Trauer, Ms Eman Aleksic and Honorary Principal Research Fellow from the TB-CRE, Associate Professor Steve Graham.
(TB in Papua New Guinea. Image courtesy: Australian Aid)